Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status-Reference-Cited by-同舟云学术

Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status

Published:2015-04-30 Issue:4 Volume:10 Page:e0125528
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Toblli Jorge Eduardo,Di Gennaro Federico

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference41 articles.

1. Iron status and hemoglobin level in chronic renal insufficiency;CY Hsu;J Am Soc Nephrol,2002

2. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure;F Locatelli;Nephrology Dialysis Transplantation,2004

3. The prevalence of anemia in patients with chronic kidney disease;W McClellan;Curr Med Res Opin,2004

4. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin;JB Post;Int Urol Nephrol,2006

5. KDIGO clinical practice guideline for anemia in chronic kidney disease;Kidney inter,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of once‐daily tacrolimus formulations in de novo liver transplant recipients: The PRETHI study;Clinical Transplantation;2023-08-24

2. Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study;World Journal of Clinical Cases;2023-04-26

3. Anemia and iron in internal medicine: an Italian survey and a review on iron intravenous therapy in medical patients;Italian Journal of Medicine;2022-10-18

4. Efficacy, Safety and Pharmacoeconomic Analysis of Intravenous Ferric Carboxymaltose in Anemic Hemodialysis Patients Unresponsive to Ferric Gluconate Treatment: A Multicenter Retrospective Study;Journal of Clinical Medicine;2022-09-07

5. Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study;Clinical Transplantation;2021-12-17